Immune Responses and Exacerbations in Severe Asthma

Overview

Journal Curr Opin Immunol

Publisher Elsevier

Specialty Allergy & Immunology

Date 2021 Mar 27

PMID 33773471

Citations 9

Authors

Matthew J Camiolo

Sagar L Kale

Timothy B Oriss

Marc Gauthier

Anuradha Ray

Affiliations

Soon will be listed here.

Abstract

Asthma as a clinical entity manifests with a broad spectrum of disease severity. Unlike milder asthma, severe disease is poorly controlled by inhaled corticosteroids, the current standard of care. Transcriptomic data, along with patient characteristics and response to biologics show that though Type 2 (T2) immune response remains an integral feature of asthma, additional molecular and immunologic factors may play important roles in pathogenesis. Mechanisms of T2 development, cellular sources of T2 cytokines and their relationship to additional immune pathways concurrently activated may distinguish several different subphenotypes, and perhaps endotypes of asthma, with differential response to non-specific and targeted anti-inflammatory therapies. Recent data have also associated non-T2 cytokines derived from T cells, particularly IFN-γ, and epithelial mediators with severe asthma. These topics and their relationships to acute asthma exacerbations are discussed in this review.

Citing Articles

A Heuristic Approach to Analysis of the Genetic Susceptibility Profile in Patients Affected by Airway Allergies.

Lio D, Di Lorenzo G, Brusca I, Scola L, Bellia C, La Piana S Genes (Basel). 2024; 15(8).

PMID: 39202464 PMC: 11353610. DOI: 10.3390/genes15081105.

Bronchial Asthma and COVID-19: Etiology, Pathological Triggers, and Therapeutic Considerations.

Starshinova A, Borozinets A, Kulpina A, Sereda V, Rubinstein A, Kudryavtsev I Pathophysiology. 2024; 31(2):269-287.

PMID: 38921725 PMC: 11206645. DOI: 10.3390/pathophysiology31020020.

Progress in diagnosis and treatment of difficult-to-treat asthma in children.

Zhou X, Zhang P, Tan H, Dong B, Jing Z, Wu H Ther Adv Respir Dis. 2023; 17:17534666231213637.

PMID: 38069568 PMC: 10710755. DOI: 10.1177/17534666231213637.

The upregulation of peripheral CD3CD56CD16 natural killer cells correlates with Th1/Th2 imbalance in asthma patients during acute upper respiratory viral infections.

Liu M, Zhang Y, Hu Y, Guo Z, Dong L BMC Immunol. 2023; 24(1):40.

PMID: 37865742 PMC: 10590514. DOI: 10.1186/s12865-023-00575-y.

Bronchial epithelial cell transcriptional responses to inhaled corticosteroids dictate severe asthmatic outcomes.

Ginebaugh S, Hagner M, Ray A, Erzurum S, Comhair S, Denlinger L J Allergy Clin Immunol. 2023; 151(6):1513-1524.

PMID: 36796454 PMC: 10257752. DOI: 10.1016/j.jaci.2023.01.028.

References

Kuo C, Pavlidis S, Loza M, Baribaud F, Rowe A, Pandis I . T-helper cell type 2 (Th2) and non-Th2 molecular phenotypes of asthma using sputum transcriptomics in U-BIOPRED. Eur Respir J. 2017; 49(2). DOI: 10.1183/13993003.02135-2016. View

Wisniewski J, Muehling L, Eccles J, Capaldo B, Agrawal R, Shirley D . T1 signatures are present in the lower airways of children with severe asthma, regardless of allergic status. J Allergy Clin Immunol. 2017; 141(6):2048-2060.e13. PMC: 5860937. DOI: 10.1016/j.jaci.2017.08.020. View

Novak N, Cabanillas B . Viruses and asthma: the role of common respiratory viruses in asthma and its potential meaning for SARS-CoV-2. Immunology. 2020; 161(2):83-93. PMC: 7405154. DOI: 10.1111/imm.13240. View

Ray A, Raundhal M, Oriss T, Ray P, Wenzel S . Current concepts of severe asthma. J Clin Invest. 2016; 126(7):2394-403. PMC: 4922699. DOI: 10.1172/JCI84144. View

Liu S, Zhi Y, Ying S . COVID-19 and Asthma: Reflection During the Pandemic. Clin Rev Allergy Immunol. 2020; 59(1):78-88. PMC: 8830198. DOI: 10.1007/s12016-020-08797-3. View

Wechsler M, Colice G, Griffiths J, Almqvist G, Skarby T, Piechowiak T . SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma. Respir Res. 2020; 21(1):264. PMC: 7550846. DOI: 10.1186/s12931-020-01503-z. View

Broadhurst R, Peterson R, Wisnivesky J, Federman A, Zimmer S, Sharma S . Asthma in COVID-19 Hospitalizations: An Overestimated Risk Factor?. Ann Am Thorac Soc. 2020; 17(12):1645-1648. PMC: 7706599. DOI: 10.1513/AnnalsATS.202006-613RL. View

Moore W, Bleecker E, Curran-Everett D, Erzurum S, Ameredes B, Bacharier L . Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol. 2007; 119(2):405-13. PMC: 2837934. DOI: 10.1016/j.jaci.2006.11.639. View

Behr F, Parga-Vidal L, Kragten N, van Dam T, Wesselink T, Sheridan B . Tissue-resident memory CD8 T cells shape local and systemic secondary T cell responses. Nat Immunol. 2020; 21(9):1070-1081. DOI: 10.1038/s41590-020-0723-4. View

10.

Bhalla A, Zhao N, Rivas D, Ho T, Perez de Llano L, Mukherjee M . Exacerbations of Severe Asthma While on Anti-IL-5 Biologics. J Investig Allergol Clin Immunol. 2020; 30(5):307-316. DOI: 10.18176/jiaci.0628. View

11.

Sabogal Pineros Y, Bal S, Dijkhuis A, Majoor C, Dierdorp B, Dekker T . Eosinophils capture viruses, a capacity that is defective in asthma. Allergy. 2019; 74(10):1898-1909. PMC: 6852198. DOI: 10.1111/all.13802. View

12.

Busse W, Holgate S, Kerwin E, Chon Y, Feng J, Lin J . Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med. 2013; 188(11):1294-302. DOI: 10.1164/rccm.201212-2318OC. View

13.

Woodruff P, Boushey H, Dolganov G, Barker C, Yang Y, Donnelly S . Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci U S A. 2007; 104(40):15858-63. PMC: 2000427. DOI: 10.1073/pnas.0707413104. View

14.

Brusselle G, Germinaro M, Weiss S, Zangrilli J . Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils. Pulm Pharmacol Ther. 2017; 43:39-45. DOI: 10.1016/j.pupt.2017.01.011. View

15.

Vieira Braga F, Kar G, Berg M, Carpaij O, Polanski K, Simon L . A cellular census of human lungs identifies novel cell states in health and in asthma. Nat Med. 2019; 25(7):1153-1163. DOI: 10.1038/s41591-019-0468-5. View

16.

Denlinger L, Phillips B, Ramratnam S, Ross K, Bhakta N, Cardet J . Inflammatory and Comorbid Features of Patients with Severe Asthma and Frequent Exacerbations. Am J Respir Crit Care Med. 2016; 195(3):302-313. PMC: 5328178. DOI: 10.1164/rccm.201602-0419OC. View

17.

Nagasaki T, Matsumoto H, Kanemitsu Y, Izuhara K, Tohda Y, Kita H . Integrating longitudinal information on pulmonary function and inflammation using asthma phenotypes. J Allergy Clin Immunol. 2014; 133(5):1474-7, 1477.e1-2. DOI: 10.1016/j.jaci.2013.12.1084. View

18.

Castro M, Corren J, Pavord I, Maspero J, Wenzel S, Rabe K . Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. 2018; 378(26):2486-2496. DOI: 10.1056/NEJMoa1804092. View

19.

Menzies-Gow A, Colice G, Griffiths J, Almqvist G, Ponnarambil S, Kaur P . NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma. Respir Res. 2020; 21(1):266. PMC: 7550847. DOI: 10.1186/s12931-020-01526-6. View

20.

Bleecker E, Wechsler M, FitzGerald J, Menzies-Gow A, Wu Y, Hirsch I . Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. Eur Respir J. 2018; 52(4). PMC: 6203407. DOI: 10.1183/13993003.00936-2018. View